Article thumbnail

5-Azacytidine in Chronic Myelomonocytic Leukemia: Case Report and Review of Literature.

By M. Greco, M. Criscuolo, L. Fianchi, E. Fabiani, L. Pagano and MT. Voso

Abstract

Hypomethylating drugs are useful in the management of Myelodysplastic syndromes, but there are only few reports on chronic myelomonocycitic (CMML) leukemia patients. We describe our experience in 3 CMML patients treated with azacitidine. Two patients obtained partial response after 4 treatment cycles with only minor toxicity and are in continuous partial response, with stable peripheral blood counts, at 29 and 30 cycles from treatment start

Topics: Case Reports
Publisher: Università Cattolica del Sacro Cuore
OAI identifier: oai:pubmedcentral.nih.gov:3103239
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (2010). Activity of azacitidine in chronic myelomonocytic leukemia.
  2. (2007). Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia. Cancer.
  3. (2010). Analysis of genome-wide methylation and gene expression induced by 5-aza-2'-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. Leuk Lymphoma.
  4. (2011). Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.
  5. (2006). Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study.
  6. (2010). Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol.
  7. (2008). Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res.
  8. (2006). Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol.
  9. (2009). International Vidaza High-Risk MDS Survival Study Group. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.Lancet Oncol.
  10. new treatments for myelodysplastic syndromes.
  11. (1988). Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases. J Clin Oncol.
  12. (1976). Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group.
  13. (2002). Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol.
  14. (2009). The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia.
  15. (2009). Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res.
  16. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues Lyon: